Subject Index of the Diseases Found in the Zend-Avesta

The collection of Zend fragments is the bible of ancient Iran, which is known as the Zend-Avesta that contains some points about diseases. The aim of this documentary study is the extraction and assortment of diseases of the Zend-Avesta. To this end, each disease Avesta presented was defined as unambiguously and as briefly as possible. Finally, the findings were set and classified in the following tables. The results showed that over 70 diseases were found in the Zend-Avesta, which can be categorized into 13 groups in numerical order. The diseases found in the Zand-Avesta are as follows: unknown diseases (17), bodily defects/ infirmities (12), integumentary system (9), musculoskeletal system (7), lymphatic system (5), gynecology (5), nervous system (5), poisoning (3), related subjects (3), reproductive system (3), digestive system (2), urinary system (1), and dental disorders (1). Overall, considering the diseases collected can help us better understand the medical aspects of the sacred books

Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

Objectives: This study aimed to determine the safety and immunogenicity of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). Methods: We conducted a randomized, double-blind, placebo-controlled, phase I trial. Three vaccine strengths were compared with an adjuvant-only preparation. It included two intramuscular and a third intranasal dose. Eligible participants were followed for adverse reactions. Specific IgG, secretory IgA, neutralizing antibodies, and cell-mediated immunity were assessed. Results: A total of 153 participants were enrolled (13 sentinels, 120 randomized, 20 non-randomized open-labeled for IgA assessment). No related serious adverse event was observed. The geometric mean ratios (GMRs) and 95% CI for serum neutralizing antibodies compared with placebo two weeks after the second injection were 5.82 (1.46–23.13), 11.12 (2.74–45.09), and 20.70 (5.05–84.76) in 5, 10, and 20 µg vaccine groups, respectively. The GMR for anti-RBD IgA in mucosal fluid two weeks after the intranasal dose was 23.27 (21.27–25.45) in the 10 µg vaccine group. The humoral responses were sustained for up to five months. All vaccine strengths indicated a strong T-helper 1 response. Conclusion: RCP is safe and creates strong and durable humoral and cellular immunity and good mucosal immune response in its 10 µg /200 µL vaccine strengths. Trial registration: IRCT20201214049709N1